Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2016, Article ID 2180748, 5 pages
http://dx.doi.org/10.1155/2016/2180748
Case Report

Psychosis or Obsessions? Clozapine Associated with Worsening Obsessive-Compulsive Symptoms

1Department of Hospital Pharmacy Services, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA
2Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA

Received 1 March 2016; Revised 2 May 2016; Accepted 12 May 2016

Academic Editor: Toshiya Inada

Copyright © 2016 Jonathan G. Leung and Brian A. Palmer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Kane, G. Honigfeld, J. Singer, and H. Meltzer, “Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine,” Archives of General Psychiatry, vol. 45, no. 9, pp. 789–796, 1988. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Schirmbeck and M. Zink, “Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review,” Current Neuropharmacology, vol. 10, no. 1, pp. 88–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Ertugrul, A. E. A. Yagcioglu, N. Eni, and K. M. Yazici, “Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients,” Psychiatry and Clinical Neurosciences, vol. 59, no. 2, pp. 219–222, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Bleakley, D. Brown, and D. Taylor, “Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review,” Therapeutic Advances in Psychopharmacology, vol. 1, no. 6, pp. 181–188, 2011. View at Publisher · View at Google Scholar
  5. S. Grover, N. Hazari, S. Chakrabarti, and A. Avasthi, “Relationship of obsessive compulsive symptoms/disorder with clozapine: a retrospective study from a multispeciality tertiary care centre,” Asian Journal of Psychiatry, vol. 15, pp. 56–61, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. F. Schirmbeck, D. Mier, C. Esslinger et al., “Increased orbitofrontal cortex activation associated with ‘pro-obsessive’ antipsychotic treatment in patients with schizophrenia,” Journal of Psychiatry and Neuroscience, vol. 40, no. 2, pp. 89–99, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Gahr, K. Rehbaum, and B. J. Connemann, “Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on,” Pharmacopsychiatry, vol. 47, no. 3, pp. 118–120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Englisch, C. Esslinger, D. Inta et al., “Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole,” Clinical Neuropharmacology, vol. 32, no. 4, pp. 227–229, 2009. View at Publisher · View at Google Scholar
  9. American Psychiatric Association, Desk Reference to the Diagnostic Criteria from DSM-5, American Psychiatric Publishing, Washington, DC, USA, 2013.
  10. T. Shahrour, M. Siddiq, S. Ghalib, and T. Alsaadi, “Severe relapsing clozapine-withdrawal catatonia,” Case Reports in Psychiatry, vol. 2015, Article ID 606853, 2 pages, 2015. View at Publisher · View at Google Scholar
  11. E. Stevenson, F. Schembri, D. M. Green, and J. D. Burns, “Serotonin syndrome associated with clozapine withdrawal,” JAMA Neurology, vol. 70, no. 8, pp. 1054–1055, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Ahmed, K. N. R. Chengappa, V. R. Naidu, R. W. Baker, H. Parepally, and N. R. Schooler, “Clozapine withdrawal-emergent dystonias and dyskinesias: a case series,” Journal of Clinical Psychiatry, vol. 59, no. 9, pp. 472–477, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Schirmbeck and M. Zink, “Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors,” Frontiers in Pharmacology, vol. 4, article 99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Bortolon and S. Raffard, “Self-reported psychotic-like experiences in individuals with obsessive-compulsive disorder versus schizophrenia patients: characteristics and moderation role of trait anxiety,” Comprehensive Psychiatry, vol. 57, pp. 97–105, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Schirmbeck, C. Esslinger, F. Rausch, S. Englisch, A. Meyer-Lindenberg, and M. Zink, “Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia,” Psychological Medicine, vol. 41, no. 11, pp. 2361–2373, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Poyurovsky, V. Kriss, G. Weisman et al., “Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia,” Journal of Clinical Psychiatry, vol. 64, no. 11, pp. 1300–1307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. A. M. Ruscio, D. J. Stein, W. T. Chiu, and R. C. Kessler, “The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication,” Molecular Psychiatry, vol. 15, no. 1, pp. 53–63, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. L. M. Koran, G. L. Hanna, E. Hollander, G. Nestadt, and H. B. Simpson, “Practice guideline for the treatment of patients with obsessive-compulsive disorder,” The American Journal of Psychiatry, vol. 164, no. 7, pp. 5–53, 2007. View at Google Scholar
  19. C. J. McDougle, L. C. Barr, W. K. Goodman et al., “Lack of efficacy of clozapine monotherapy in refractory obsessive- compulsive disorder,” American Journal of Psychiatry, vol. 152, no. 12, pp. 1812–1814, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. A. R. Sa, A. G. Hounie, A. S. Sampaio, J. Arrais, E. C. Miguel, and H. Elkis, “Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol,” Comprehensive Psychiatry, vol. 50, no. 5, pp. 437–442, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. A. A. Scheltema Beduin, M. Swets, M. Machielsen et al., “Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients,” Journal of Clinical Psychiatry, vol. 73, no. 11, pp. 1395–1402, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Lin, S. Su, and C. Pan, “Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms,” Therapeutic Drug Monitoring, vol. 28, no. 3, pp. 303–307, 2006. View at Publisher · View at Google Scholar
  23. C. Andrade, “Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia,” Journal of Clinical Psychiatry, vol. 73, no. 11, pp. e1362–e1364, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. J. S. Markowitz, H. S. Gill, M. Lavia, T. D. Brewerton, and C. L. DeVane, “Fluvoxamine-clozapine dose-dependent interaction,” Canadian Journal of Psychiatry, vol. 41, no. 10, pp. 670–671, 1996. View at Google Scholar · View at Scopus
  25. S. L. Cassady and G. K. Thaker, “Addition of fluoxetine to clozapine,” The American Journal of Psychiatry, vol. 149, no. 9, p. 1274, 1992. View at Google Scholar · View at Scopus
  26. R. D. Strous, J. K. Patel, S. Zimmet, and A. I. Green, “Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features,” American Journal of Psychiatry, vol. 156, no. 6, pp. 973–974, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Zink, S. Englisch, U. Knopf, A. Kuwilsky, and H. Dressing, “Augmentation of clozapine with valproic acid for clozapine-induced obsessive-compulsive symptoms,” Pharmacopsychiatry, vol. 40, no. 5, pp. 202–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. N. P. Rao, A. Antony, D. Raveendranathan et al., “Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: a case report,” The Journal of ECT, vol. 27, no. 1, pp. e37–e38, 2011. View at Publisher · View at Google Scholar
  29. M. R. Milad and S. L. Rauch, “Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways,” Trends in Cognitive Sciences, vol. 16, no. 1, pp. 43–51, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Menzies, S. R. Chamberlain, A. R. Laird, S. M. Thelen, B. J. Sahakian, and E. T. Bullmore, “Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited,” Neuroscience and Biobehavioral Reviews, vol. 32, no. 3, pp. 525–549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. M. Fonseka, M. A. Richter, and D. J. Müller, “Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature,” Current Psychiatry Reports, vol. 16, no. 11, article 510, 2014. View at Publisher · View at Google Scholar
  32. C. Tranulis, S. Potvin, M. Gourgue, G. Leblanc, A. Mancini-Marïe, and E. Stip, “The paradox of quetiapine in obsessive-compulsive disorder,” CNS Spectrums, vol. 10, no. 5, pp. 356–361, 2005. View at Google Scholar · View at Scopus
  33. S. Schönfelder, F. Schirmbeck, R. Waltereit, S. Englisch, and M. Zink, “Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia,” Clinical Neuropharmacology, vol. 34, no. 6, pp. 256–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. V. Villari, T. Frieri, and A. Fagiolini, “Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms,” Journal of Clinical Psychopharmacology, vol. 31, no. 3, pp. 375–376, 2011. View at Publisher · View at Google Scholar
  35. G. Eryilmaz, G. Hizli Sayar, E. Ozten, I. Gögcegöz Gül, and O. Karamustafalioglu, “Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia,” Annals of General Psychiatry, vol. 12, no. 1, article 40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Cai, W. Zhang, Z. Yi et al., “Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms,” Psychopharmacology, vol. 230, no. 1, pp. 49–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. N. T. Lemke and J. R. Bustillo, “Clozapine-induced obsessive-compulsive symptoms in bipolar disorder,” American Journal of Psychiatry, vol. 170, no. 8, p. 930, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. V. B. Maršanić, B. Aukst-Margetić, N. Grgić, and E. Kušmić, “Misdiagnosis and exacerbation of unusual obsessive-compulsive disorder presentation with risperidone and clozapine in an adolescent girl—a case report,” Collegium Antropologicum, vol. 35, no. 1, pp. 293–296, 2011. View at Google Scholar · View at Scopus
  39. C. A. Naranjo, U. Busto, E. M. Sellers et al., “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Publisher · View at Google Scholar